HK Stock MarketDetailed Quotes

02496 YZYBIO-B

Watchlist
  • 3.790
  • -0.010-0.26%
Market Closed Dec 13 16:08 CST
734.69MMarket Cap-3.65P/E (TTM)

About YZYBIO-B Company

Wuhan Youzhiyou Biopharmaceutical Co., Ltd. is a biotechnology company dedicated to developing bispecific antibody (BsAb) based therapy for the treatment of cancer-related complications, cancer and senile ophthalmology to address medical needs in the field of oncology and geriatric ophthalmology. The company's mission is to develop innovative medicines to protect human health. Since its establishment in 2010, Youzhibao Biotech has insisted on independent innovation, laid out and deepened the field of bispecific antibodies, and developed 4 innovative platforms, including the self-developed YBODY platform, the Check-body platform, and the nano-YBodyTM platform, and the UVAX platform developed in cooperation with the Wuhan Institute of Virology. The company has designed and developed seven clinical-stage drug candidate pipelines.

Company Profile

Symbol02496
Company NameYZYBIO-B
ISINCNE1000063C4
Listing DateSep 25, 2023
Issue Price16.00
Shares Offered11.00M share(s)
FoundedJul 8, 2010
Registered AddressChina
ChairmanZhou Pengfei
Secretaryjianhualaitianen zheng
Audit InstitutionDeloitte Guan Huang Chen Fang Certified Public Accountants
Company CategoryMainland registration of Mainland Individuals control
Registered Office666 Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, Hubei, China
Head Office and Principal Place of Business5th Floor, Manulife Plaza, 348 Kwun Tong Road, Kowloon, Hong Kong
Fiscal Year Ends12-31
Employees114
MarketHong Kong motherboard
Phone(027)82668988
Fax(027)68788819
Emailinfo@yzybio.com
Websitehttp://www.yzybio.com
Business Wuhan YZY Biopharma Co Ltd is a China-based company principally involved in the research, development, production and sales of pharmaceuticals. The Company is suspected in the research, development and industrialization of bispecific antibody drugs. The Company's main products include anti-PD1&anti-CD3, anti-CD19&anti-CD3, and anti-CDX&CD3. The Company's drug products are commonly used in major diseases such as tumors, immunity, inflammation and infection.

Company Executives

  • Name
  • Position
  • Salary
  • Zhou Pengfei
  • Chairman, CEOs, Executive Director, Chairman of the Nomination Committee, Co-founder, Authorized Representative
  • --
  • qian yuan
  • Non-executive Directors, Remuneration Committee Members, Co-founder
  • --
  • hongfeng zhou
  • Non-executive Directors, Audit Committee Members, Co-founder, Authorized Representative
  • --
  • zhenhai pang
  • Non-executive Directors
  • --
  • xiwu hui
  • Non-executive Directors
  • --
  • qian liang
  • Non-executive Directors
  • --
  • zhicheng wen
  • Non-executive Directors
  • --
  • shouwu xie
  • Non-executive Directors
  • --
  • bin cheng
  • Independent Non-Executive Director, Remuneration Committee Chairman, Nomination Committee Members
  • --
  • lili fu
  • Independent Non-Executive Director, Chairman of the Audit Committee
  • --
  • yuezhen deng
  • Independent Non-Executive Director, Audit Committee Members
  • --
  • bin chen
  • Independent Non-Executive Director, Nomination Committee Members, Remuneration Committee Members
  • --
  • jumin sun
  • Chairman of the Supervisory Committee
  • --
  • fang liu
  • Auditors
  • --
  • changtao ji
  • Auditors
  • --
  • ying xiao
  • Employee Representative Supervisor
  • 384.00K
  • jing zhang
  • Senior Director of R&D Center, auditors
  • --
  • bin yang
  • Vice President of Production Center
  • --
  • shaoyi huang
  • Senior Director of Clinical Division
  • --
  • jianhua zheng
  • Joint Company Secretary
  • --
  • tianen lai
  • Joint Company Secretary
  • --
Heat List
HK
Overall
Symbol
Price
% Chg

No Data

Investment Theme Pharmaceutical Companies
Pharmaceutical Companies
Intraday-2.21%